Dispatch Bio

Dispatch Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.

Company Details

Employees
59
Founded
-
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Looking for a particular Dispatch Bio employee's phone or email?

Dispatch Bio Questions

News

Dispatch Bio Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting - Yahoo Finance

Dispatch Bio Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Yahoo Finance

Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer - citybiz

Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer citybiz

Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach - statnews.com

Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach statnews.com

Dispatch Bio Launches to Develop Universal Solid Tumor Treatment - Inside Precision Medicine

Dispatch Bio Launches to Develop Universal Solid Tumor Treatment Inside Precision Medicine

Dispatch Bio Launches With $216M To Develop Universal CAR T Therapy for Solid Tumors - BioSpace

Dispatch Bio Launches With $216M To Develop Universal CAR T Therapy for Solid Tumors BioSpace

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy - BioPharma Dive

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy BioPharma Dive

Karen Knudsen: Celebrating Dispatch Bio and the PICI Model in Action - Oncodaily

Karen Knudsen: Celebrating Dispatch Bio and the PICI Model in Action Oncodaily

Cancer biotech Dispatch unveils with $216M and CAR-T pioneer Carl June as cofounder - Fierce Biotech

Cancer biotech Dispatch unveils with $216M and CAR-T pioneer Carl June as cofounder Fierce Biotech

Well-backed Dispatch Bio goes forth to slay solid tumors - The Pharma Letter

Well-backed Dispatch Bio goes forth to slay solid tumors The Pharma Letter

Startup Dispatch Bio has ambitious plan (and $216 million) to battle cancer - San Francisco Business Times - The Business Journals

Startup Dispatch Bio has ambitious plan (and $216 million) to battle cancer - San Francisco Business Times The Business Journals

Dispatch Bio Launched With $216 Million To Develop Solid Tumor Treatments - Pulse 2.0

Dispatch Bio Launched With $216 Million To Develop Solid Tumor Treatments Pulse 2.0

Dispatch Bio Raises Series A in Funding; Total To $216M - FinSMEs

Dispatch Bio Raises Series A in Funding; Total To $216M FinSMEs

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach - BioSpace

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach BioSpace

Top Dispatch Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant